Health TrialsbyHealthPanel

Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.

ConditionsAtrial Fibrillation (AF)Obesity & Overweight
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Eastern Finland

About this trial

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited.

The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18-75 years

Body mass index (BMI) ≥27 kg/m²

Documented atrial fibrillation (paroxysmal or persistent)

Ability to participate in exercise training and follow study procedures

Disqualifiers

Permanent atrial fibrillation

Unstable angina pectoris or acute coronary syndrome within the past 3 months

Participation in other lifestyle or drug weight reduction trials

Significant left ventricular dysfunction (ejection fraction <30%)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Tailored Exercise and Dietary Lifestyle Program

    Behavioral

    A 12-month tailored lifestyle program combining individualized aerobic exercise, muscle strength training, and dietary counseling. The program includes home-based aerobic training 2-5 times per week, muscle strength training, group-based dietary intervention sessions, and motivational support. The intervention is added to standard clinical care for atrial fibrillation.

  • Usual Clinical Care

    Other intervention

    Participants receive standard clinical care for atrial fibrillation according to the guideline-based routine practice at participating hospitals. No structured exercise or dietary lifestyle intervention is provided.

Treatment groups

158 Participants
are divided into 2 treatment groups
Group A: 12-Month Tailored Exercise and Dietary Lifestyle InterventionExperimental treatment 1 intervention
Group B: Usual Clinical CareOther 1 intervention

Trial outcomes

Primary outcomes

1

Atrial Fibrillation Burden

Total atrial fibrillation burden measured by continuous rhythm monitoring over the intervention period. Unit of Measure: Percentage of time in atrial fibrillation (%)

Time frame
12 months

Secondary outcomes

1

Cardiac Fat Mass

Epicardial and pericardial fat volume measured by cardiac MRI. Unit of Measure: Milliliters (ml).

Time frame
12 months
2

AF Symptom Severity

Symptom severity assessed using the Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT). Unit of Measure: Score on a 0-100 scale. Interpretation: Higher scores indicate better AF-related quality of life (i.e., fewer or less severe symptoms).

Time frame
12 months
3

Body Fat Mass

Total body fat mass assessed using a body composition analyzer. Unit of Measure: Kilograms (kg)

Time frame
12 months
4

Six-Minute Walk Test (6MWT)

Functional exercise capacity assessed using the Six-Minute Walking Test (6MWT). Unit of Measure: Meters walked in 6 minutes. Interpretation: Higher values indicate better functional capacity.

Time frame
12 months

Other outcomes

1

Natriuretic Peptides

Natriuretic propeptides, proBNP, Unit: pg/mL

Time frame
12 months
2

Dietary assessment

Dietary intake assessed using repeated 4-day food records. Unit of Measure: Nutrient intake per day (g/day, kcal/day).

Time frame
12 months
3

Physical Activity Level

Daily physical activity and sedentary time measured by accelerometry. Unit of Measure: Minutes per day (min/day).

Time frame
12 months
4

Inflammatory Markers

Inflammatory marker changes (C-reactive protein, CRP) Unit: mg/L

Time frame
12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Eastern Finland

Lead sponsor

Kuopio University Hospital

Collaborator

Tampere University Hospital

Collaborator

UKK Institute

Collaborator

Hospital Nova, Central Finland

Collaborator

Source ClinicalTrials.gov
Apply now